Wolff-Parkinson-White syndrome consensus statement: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(13 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Wolff-Parkinson-White syndrome}}
{{Wolff-Parkinson-White syndrome}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[User:Kashish Goel|Kashish Goel, M.D.]]
{{CMG}}; '''Associate Editor-In-Chief:''' {{Sara.Zand}} {{CZ}}; [[User:Kashish Goel|Kashish Goel, M.D.]]
==PACES/HRS Expert Consensus - Recommendations for Risk Stratification (DO NOT EDIT)==
<ref name="pmid22579340">{{cite journal |author=Cohen MI, Triedman JK, Cannon BC, ''et al.'' |title=PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern: Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume= |issue= |pages= |year=2012 |month=May |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050 |url=}}</ref>
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===
{{cquote|
'''1.''' An exercise stress test, when the child is old enough to comply, is a reasonable component of the evaluation if the ambulatory ECG exhibits persistent preexcitation ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]/[[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''. In patients with clear and abrupt loss of preexcitation at physiological heart rates, the accessory pathway properties pose a lower risk of sudden death. In children with subtle preexcitation the ECG and exercise test may be difficult to interpret.


'''2.''' Utilization of invasive risk stratification (transesophageal or intracardiac) to assess the shortest preexcited R-R interval in atrial fibrillation is reasonable in individuals whose noninvasive testing does not demonstrate clear and abrupt loss of preexcitation.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]/[[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''}}


==PACES/HRS Expert Consensus - Recommendations for Catheter Ablation (DO NOT EDIT)==
== Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation ==  
<ref name="pmid22579340">{{cite journal |author=Cohen MI, Triedman JK, Cannon BC, ''et al.'' |title=PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern: Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume= |issue= |pages= |year=2012 |month=May |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050|url=}}</ref>
* '''2015 ACC-AHA Guideline'''<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref>
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===


{{cquote|
{| class="wikitable"
3. Young patients with a Shortest Pre-Excited R-R Interval (SPERRI) ≤250 ms in atrial fibrillation are at increased risk for sudden cardiac death (SCD). It is reasonable to consider catheter ablation in this group, taking into account the procedural risk factors based on the anatomical location of the pathway. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]/[[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
|-
!  Class of Recommendation(COR) !! Recommendations
|-
|    1    || In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over
manifest pathway during [[exercise testing]] in [[sinus rhythm]] or
intermittent loss of-excitation during [[ECG]] or ambulatory monitoring is useful to identify patients at low risk of rapid conduction over the pathway
|-
| 2a || An [[EP study]] is reasonable in asymptomatic patients with pre-excitation to risk-stratify for
arrhythmic events
|-
| 2a || [[Catheter ablation]] of the [[accessory pathway]] is reasonable in asymptomatic [[patients]] with pre-
excitation if an [[EP study]] identifies a high risk of [[arrhythmic]] events, including rapidly conducting
pre-excited [[AF]]
|-
| 2a || [[Catheter ablation]] of the accessory pathway is reasonable in asymptomatic patients if the presence of
pre-excitation precludes specific employment(such as with [[pilots]])
|-
| 2a || Observation,without further evaluation or treatment,is reasonable in asymptomatic patients
with pre-excitation
|}


4. Young patients with a SPERRI >250 ms in atrial fibrillation are at lower risk for SCD, and it is reasonable to defer ablation. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' Ablation may be considered in these patients at the time of diagnostic study if the location of the pathway and/or patient characteristics do not suggest that ablation may incur an increased risk of adverse events, such as AV block or coronary artery injury ''(Class IIB, [[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''


5. Young patients deemed to be at low risk might subsequently develop cardiovascular symptoms such as syncope or palpitations. These patients should then be considered symptomatic and may be eligible for catheter ablation procedures regardless of the prior assessment.
== Recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways ==
* '''2015 ACC-AHA Guideline'''<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref>


 
{| class="wikitable"
===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]===
|-
6. Asymptomatic patients with a WPW ECG pattern and structural heart disease are at risk for both atrial tachycardia and AV reciprocating tachycardia, which may result in unfavorable hemodynamics. Ablation may be considered regardless of the anterograde characteristics of the accessory pathway. '([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''.
! Class of Recommendation !! Recommendations
 
|-
7. Asymptomatic patients with a WPW ECG pattern and ventricular dysfunction secondary to dyssynchronous contractions may be considered for ablation, regardless of anterograde characteristics of the bypass tract. '([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''.}}
| 1 || In symptomatic patients with [[pre-excitation]], the findings of abrupt loss of conduction over the
 
pathway during [[exercise testing]] in [[sinus rhythm]] or intermittent loss
==PACES/HRS Expert Consensus - Special Considerations (DO NOT EDIT)==
of [[pre-excitation]] during [[ECG]] or ambulatory monitoring are useful for
<ref name="pmid22579340">{{cite journal |author=Cohen MI, Triedman JK, Cannon BC, ''et al.'' |title=PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern: Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume= |issue= |pages= |year=2012 |month=May |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050|url=}}</ref>
identifying patients at lower risk of developing rapid conduction over the[[ pathway]]
 
|-
{{cquote|
| 1 || An EP study is useful in symptomatic patients with [[pre-excitation]] to risk-stratify for
8. Asymptomatic patients with a WPW ECG pattern may be prescribed ADHD medications. This recommendation follows the American Heart Association Guidelines, which state that ADHD medications may be used in this setting after cardiac evaluation and with intermittent monitoring and supervision of a pediatric cardiologist.<ref name="pmid18427125">{{cite journal |author=Vetter VL, Elia J, Erickson C, ''et al.'' |title=Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing |journal=Circulation |volume=117 |issue=18 |pages=2407–23 |year=2008 |month=May |pmid=18427125 |doi=10.1161/CIRCULATIONAHA.107.189473 |url=}}</ref>}}
life-threatening [[arrhythmic]] events
|}


==References==
==References==

Latest revision as of 06:24, 15 September 2020

Wolff-Parkinson-White syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Wolff-Parkinson-White syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Approach

History and Symptoms

Electrocardiogram

EKG Examples

Other Diagnostic Studies

Treatment

Risk Stratification

Cardioversion

Medical Therapy

Catheter Ablation

Prophylaxis

Consensus Statement

Case Studies

Case #1

Wolff-Parkinson-White syndrome consensus statement On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wolff-Parkinson-White syndrome consensus statement

CDC onWolff-Parkinson-White syndrome consensus statement

Wolff-Parkinson-White syndrome consensus statement in the news

Blogs on Wolff-Parkinson-White syndrome consensus statement

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Wolff-Parkinson-White syndrome consensus statement

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]; Kashish Goel, M.D.


Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation

  • 2015 ACC-AHA Guideline[1]
Class of Recommendation(COR) Recommendations
1 In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over

manifest pathway during exercise testing in sinus rhythm or intermittent loss of-excitation during ECG or ambulatory monitoring is useful to identify patients at low risk of rapid conduction over the pathway

2a An EP study is reasonable in asymptomatic patients with pre-excitation to risk-stratify for

arrhythmic events

2a Catheter ablation of the accessory pathway is reasonable in asymptomatic patients with pre-

excitation if an EP study identifies a high risk of arrhythmic events, including rapidly conducting pre-excited AF

2a Catheter ablation of the accessory pathway is reasonable in asymptomatic patients if the presence of

pre-excitation precludes specific employment(such as with pilots)

2a Observation,without further evaluation or treatment,is reasonable in asymptomatic patients

with pre-excitation


Recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways

  • 2015 ACC-AHA Guideline[1]
Class of Recommendation Recommendations
1 In symptomatic patients with pre-excitation, the findings of abrupt loss of conduction over the

pathway during exercise testing in sinus rhythm or intermittent loss of pre-excitation during ECG or ambulatory monitoring are useful for identifying patients at lower risk of developing rapid conduction over thepathway

1 An EP study is useful in symptomatic patients with pre-excitation to risk-stratify for

life-threatening arrhythmic events

References

  1. ↑ 1.0 1.1 Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Wolff-Parkinson-White_syndrome_consensus_statement&oldid=1662523"